Baird analyst David Rescott downgraded Penumbra (PEN) to Neutral from Outperform with a price target of $374, up from $345. The firm cites the pending acquisition by Boston Scientific for the downgrade.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN: